GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced that ProFound Therapeutics and Quotient Therapeutics have entered into separate ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GlaxoSmithKline (GSK) has announced the purchase of 243,000 of its own ordinary shares ...

A strong performer already, GSK stock is trading up 44% in 2025, yet its stock remains a good bargain. GSK trades for a ...

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership ...

British Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned investment in U.S. R&D and manufacturing. The funds are set to be spread ...

GSK and Flagship Pioneering announced a collaboration on Monday morning to discover and develop a portfolio of medicines and vaccines, with a focus on respiratory and immunology therapeutic areas.

GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to ...

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors to prevent disease, potentially ...